Severe asthma: Oral corticosteroids maintenance therapy associated with toxicity

Pneumonia and osteopenia had the highest prevalence of adverse events after long-term oral corticosteroid use in patients with severe asthma in the ongoing, multicentre CHRONICLE study. The authors recommend systemic corticosteroid-sparing treatment strategies for severe asthma patients [1]. “Oral corticosteroids are widely used in patients with the most severe forms of asthma, but the outcome is not well understood,” said Prof. Njira Lugogo (University of Michigan, USA). There is a growing recognition of the adverse consequences of maintenance systemic corticosteroid therapy in asthma treatment [2]. However, only a few studies have assessed this effect in severe asthma patients with a specialist-confirmed diagnosis. The CHRONICLE study is an ongoing, non-interventional, observational study of adults with severe asthma. Participants receive biologic treatments and/or maintenance systemic cortico...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 29 October, 202029 October, 2020